The cancer therapeutics market size is poised to grow by $ 393.61 billion by 2032 from $ 164 Billion in 2022, exhibiting a CAGR of 9.20% during the forecast period 2023-2032.
The main objective of this report is to define, describe, and forecast the global market by types, application, manufacturers, and regions. The report provides detailed information about the major factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the market. The report aims to strategically analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global market. The report also attempts to forecast the market size of the 5 main regions: North America, Europe, Asia Pacific (APAC), Middle East and Africa (MEA), and Latin America. It strategically profiles the key market players and comprehensively analyzes their core competencies. It also tracks and analyzes competitive developments, such as joint ventures, mergers and acquisitions, new developments, and Research and Development (R&D) activities, in market.
Get a Sample: https://www.precedenceresearch.com/sample/1546
COVID-19 Impact
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the CANCER THERAPEUTICS market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Major companies operating in this area
- F. Hoffmann-La Roche AG
- Bristol-Myers Squibb Company
- AbbVie, Inc.
- Johnson & Johnson
- Celgene Corporation
- AstellasPharma, Inc.
- Pfizer, Inc.
- Novartis AG
- Merck KGaA
- Eli Lilly and Company
Market Segmentation
By Application
- Blood Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Breast Cancer
- Cervical Cancer
- Head and Neck Cancer
- Glioblastoma
- Malignant Meningioma
- Mesothelioma
- Melanoma
- Others
By Top Selling Drugs
- Revlimid
- Avastin
- Herceptin
- Rituxan
- Opdivo
- Gleevec
- Velcade
- Imbruvica
- Ibrance
- Zytiga
- Alimta
- Xtandi
- Tarceva
- Perjeta
- Temodar
- Others
By End User
- Hospitals
- Specialty Clinics
- Cancer and Radiation Therapy Centers
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Major highlights of Report:
- Figures related to sales volume, market remuneration, and segmental shares
- Featuring market dynamics
- Growth prospects and expansion graph
- PROCON study of direct & indirect sales channels
- Profiles of prominent traders, dealer, and distributors in the industry
Geographical landscape: North America, Europe, Asia-Pacific, South America, Middle East and Africa
- Industry forecasts based on region and at country level
- Data about sales volume recorded, industry share held, and profit margins amassed
- Overall remuneration and estimated growth rate for each regional market
Major Key Points Covered in Report:
Executive Summary: It includes key trends of the CANCER THERAPEUTICS market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the CANCER THERAPEUTICS market based on production and revenue.
Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.
Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the CANCER THERAPEUTICS market.
Market Segments: This part of the report discusses product, application and other segments of the CANCER THERAPEUTICS market based on market share, CAGR, market size, and various other factors.
Research Methodology: This section discusses the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Therapeutics Market
5.1. COVID-19 Landscape: Cancer Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Therapeutics Market, By Top Selling Drugs
8.1. Cancer Therapeutics Market, by Top Selling Drugs Type, 2023-2032
8.1.1. Revlimid
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Avastin
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Herceptin
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Rituxan
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Opdivo
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Gleevec
8.1.6.1. Market Revenue and Forecast (2020-2032)
8.1.7. Velcade
8.1.7.1. Market Revenue and Forecast (2020-2032)
8.1.8. Imbruvica
8.1.8.1. Market Revenue and Forecast (2020-2032)
8.1.9. Ibrance
8.1.9.1. Market Revenue and Forecast (2020-2032)
8.1.10. Zytiga
8.1.10.1. Market Revenue and Forecast (2020-2032)
8.1.11. Alimta
8.1.11.1. Market Revenue and Forecast (2020-2032)
8.1.12. Xtandi
8.1.12.1. Market Revenue and Forecast (2020-2032)
8.1.13. Tarceva
8.1.13.1. Market Revenue and Forecast (2020-2032)
8.1.14. Perjeta
8.1.14.1. Market Revenue and Forecast (2020-2032)
8.1.15. Temodar
8.1.15.1. Market Revenue and Forecast (2020-2032)
8.1.16. Others
8.1.16.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Cancer Therapeutics Market, By Application
9.1. Cancer Therapeutics Market, by Application, 2023-2032
9.1.1. Blood Cancer
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Lung Cancer
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Colorectal Cancer
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Prostate Cancer
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Breast Cancer
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Cervical Cancer
9.1.6.1. Market Revenue and Forecast (2020-2032)
9.1.7. Head and Neck Cancer
9.1.7.1. Market Revenue and Forecast (2020-2032)
9.1.8. Glioblastoma
9.1.8.1. Market Revenue and Forecast (2020-2032)
9.1.9. Malignant Meningioma
9.1.9.1. Market Revenue and Forecast (2020-2032)
9.1.10. Mesothelioma
9.1.10.1. Market Revenue and Forecast (2020-2032)
9.1.11. Melanoma
9.1.11.1. Market Revenue and Forecast (2020-2032)
9.1.12. Others
9.1.12.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Cancer Therapeutics Market, By End User
10.1. Cancer Therapeutics Market, by End User, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Cancer and Radiation Therapy Centers
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Cancer Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.1.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.3. Market Revenue and Forecast, by End User (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.2.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.6.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.7.3. Market Revenue and Forecast, by End User (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.3.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.6.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.7.3. Market Revenue and Forecast, by End User (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.6.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.7.3. Market Revenue and Forecast, by End User (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Top Selling Drugs (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.5.3. Market Revenue and Forecast, by End User (2020-2032)
Chapter 12. Company Profiles
12.1. F. Hoffmann-La Roche AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol-Myers Squibb Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. AbbVie, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Johnson & Johnson
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Celgene Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. AstellasPharma, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Novartis AG
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Merck KGaA
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Eli Lilly and Company
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments